ADC THERAPEUTICS SA (ADCT) (ADCT)
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotech built around ZYNLONTA (loncastuximab tesirine), an approved CD19-directed antibody-drug conjugate (ADC). Zamperini previously wrote up ADCT at ~$4/sh, but the stock has since cratered ~70% on the company’s LOTIS-5 topline data. Although LOTIS-5 met its primary endpoint (PFS HR 0.73, p=0.008), the data were worse than expected. However, we believe the commercial impact of the Lotis 5 “miss” is minimal. Thus, the recent sell-off creates an incredible buying opportunity.
0 likes · 0 comments · 5d ago